FDA replaces Women’s Health director

Share this article:
The FDA named Theresa Toigo acting director of its Office of Women's Health (OWH).
She replaces Susan Wood, who quit this month in protest after the agency refused to permit OTC sales of Barr's Plan B emergency contraceptive.
Toigo is an FDA veteran who also heads the agency's Office of Special Health Issues.
The FDA will conduct a search for a permanent replacement, an FDA spokeswoman told MM&M, although a timeframe for finding a permanent OWH director is not being given.
Dr. Lester Crawford, FDA commissioner, announced Toigo's appointment Friday.
Crawford's own confirmation had been held up by Senate Democrats until the administration set a Sept. 1 deadline for FDA to make a decision on Plan B. On Aug. 26, however, Crawford ordered a 60-day public comment period on Plan B, saying the regulatory and policy issues raised by Barr's application -- i.e., whether Plan B can switch to OTC status for women ages 16 and older and remain Rx status for women under 16 -- were too weighty to be decided behind closed doors.
Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...